Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1985 • ACR Convergence 2022
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
Thomas Jonassen¹, Irene Sandholdt², Birgitte Telmer² and Ellen-Margrethe Hauge³, ¹SynAct Pharma, Holte, Denmark, ²CroxxMed, Hørsholm, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammatory activity and the promotion of inflammatory resolution. AP1189 is novel biased…
Abstract Number: 2251 • ACR Convergence 2022
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Matthew Baker¹, Yuhan Liu¹, Rong Lu¹, Janice Lin¹, Jason Melehani¹ and William Robinson², ¹Stanford University, Stanford, CA, ²Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
Abstract Number: 0270 • ACR Convergence 2022
Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
Kristin Schmiedeberg¹, Irene Abela², Nicolas Vuilleumier³, Johannes von Kempis⁴ and Andrea Rubbert-Roth⁵, ¹Cantonal Hospital St Gallen, St.Gallen, Switzerland, ²Institute of Medical Virology, University of Zurich, Zürich, Switzerland, ³Laboratory Medicine Division, University of Geneva, Geneva, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: Anti-SARS-CoV2 mRNA vaccination may result in blunted humoral immune responses with lower peak titers and a different kinetic in patients with rheumatic diseases receiving…
Abstract Number: 0349 • ACR Convergence 2022
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
Emma Materne¹, Hyon Choi², Baijun Zhou¹, Karen Costenbader³, Yuqing Zhang⁴ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA
Background/Purpose: Belimumab, a biologic B-Lymphocyte stimulator (BLyS) inhibitor, was FDA-approved in 2011 for the treatment of active SLE. Initial phase 3 placebo-controlled trials found no…
Abstract Number: 0714 • ACR Convergence 2022
Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
Yinzhu Jin, Jun Liu, Rishi Desai and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Serostatus may be associated with different responses to treatment with biologic disease-modifying anti-rheumatic drugs (DMARD) or Janus kinase inhibitors (JAKi) in patients with rheumatoid…
Abstract Number: 0908 • ACR Convergence 2022
The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis
Arkady Manning-Bennett¹, Ashley Hopkins², Michael Sorich², Susanna Proudman³, David Foster¹, Ahmad Abuhelwa² and Michael Wiese¹, ¹University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that is characterised by inflammation in the synovium of diarthrodial joints and low-level inflammation in multiple…
Abstract Number: 0981 • ACR Convergence 2022
QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study
Tanmayee Bichile¹, Susan Manzi² and Tarun Sharma³, ¹Allegheny Health Network, Gibsonia, PA, ²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ³Allegheny Health Network, Pittsburgh, PA
Background/Purpose: The effect of hydroxychloroquine (HCQ) on QTc interval in patients with rheumatic diseases is under scrutiny since the COVID-19 pandemic, however studies have shown…
Abstract Number: 1399 • ACR Convergence 2022
Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
Gregory McDermott¹, Jing Cui¹, Rachel Knevel², Kumar Dahal¹, Dana Weisenfeld¹, Priyam Das³, Elizabeth Karlson¹, Su-Chun Cheng⁴, Soumya Raychaudhuri¹, Tianxi Cai⁴ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Leiden University Medical Center, Leiden, Netherlands, ³Harvard Medical School, Boston, MA, ⁴Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1679 • ACR Convergence 2022
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Yukiko Kimura¹, Sarah Ringold², George Tomlinson³, Laura Schanberg⁴, Anne Dennos⁵, MaryEllen Riordan⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Pamela Weiss⁹, Brian Feldman¹⁰, Mei Sing Ong¹¹ and Marc Natter¹², ¹Hackensack Meridian Health, New York, NY, ²Janssen, Seattle, WA, ³University of Toronto, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷CARRA, Inc, Washington, DC, ⁸CARRA, Inc, New Orleans, LA, ⁹Children's Hospital of Philadelphia, Glen Mills, PA, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹Harvard Pilgrim Institute, Boston, MA, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
Abstract Number: 1989 • ACR Convergence 2022
Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Nada Alrifai¹, Mohamed Tageldin², Malavikalakshmi Attur², Nicholas Wilson², Rebecca schorr² and Tarun Sharma², ¹Allegheny Health Network, Pittsburgh, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Few RCTs and real-world studies…
Abstract Number: 2262 • ACR Convergence 2022
Albumin-hitchhiking MMP13 siRNA Conjugate (siMMP13< (EG18L)2) for the Treatment of Rheumatic Disease
Juan Colazo¹, Ella Hoogenboezem¹, Fang Yu¹, Veeraj Shah¹, Justin Lo¹, Hongsik Cho², Karen Hasty², Leslie Crofford³ and Craig Duvall¹, ¹Department of Biomedical Engineering, Vanderbilt University, Nashville, Nashville, TN, ²Department of Orthopaedic Surgery and Biomedical Engineering, Memphis VA Medical Center, Memphis, TN, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis (RA) decrease quality of life due to joint destruction, pain, and decreased function. Multiple joint osteoarthritis (MJOA) can occur…
Abstract Number: 0274 • ACR Convergence 2022
Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
Sabina Ciciriello¹, Geoffrey Littlejohn², Tamas Treuer³, Kathryn Gibson⁴, Peter Youssef⁵, Paul Bird⁶, Catherine OSullivan⁷, Tegan Smith⁸ and Claire Deakin⁹, ¹Melbourne Health, Melbourne, Australia, ²OPAL Rheumatology Ltd, Melbourne, Australia, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, United States of America, Sydney, Australia, ⁵University of Sydney, Sydney, Australia, ⁶University of New South Wales, Sydney, Australia, ⁷OPAL Rheumatology Ltd, Sydney, Australia, ⁸OPAL Rheumatology Ltd, Geelong, Australia, ⁹OPAL Rheumatology Ltd, Mosman, Australia
Background/Purpose: JAK inhibitors (JAKi) have been a major development in treatment for many patients with RA due to their ability to block multiple cytokine pathways…
Abstract Number: 0367 • ACR Convergence 2022
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
April Jorge¹, Baijun Zhou¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Patients with SLE are at increased risk of COVID-19 and its severe outcomes, in part due to the use of immunosuppressants. We sought to…
Abstract Number: 0732 • ACR Convergence 2022
Application of Natural Language Processing to Identify Varicella Zoster Infection in Clinical Notes
Austin Ho¹, Zara Izadi², Gabriela Schmajuk³, Jinoos Yazdany⁴, Suzanne Tamang⁵ and Milena Gianfrancesco⁶, ¹University of California, Berkeley, Berkeley, CA, ²University of California San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Stanford Center for Population Health Sciences, Redwood City, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Varicella zoster virus (VZV) infection can be associated with significant morbidity in immunosuppressed individuals. However, infections of VZV are often documented in unstructured fields…
Abstract Number: 0913 • ACR Convergence 2022
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
Karam Jabri¹, Linda Burns² and Joseph Grisanti³, ¹University at Buffalo/Catholic Health, Depew, NY, ²Buffalo Rheumatology, Lancaster, NY, ³Buffalo Rheumatology & Medicine, Orchard Park, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of infection compared to healthy subjects (1). This is because of a multifactorial complex…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].